NCT06846489View on ClinicalTrials.gov

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

February 10, 2033

Study Completion Date

February 20, 2033

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
DRUG

Acalabrutinib

100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment.

DRUG

Rituximab

375 mg/m² IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months

Trial Locations (1)

51000

RECRUITING

Sun yat-sen university cancer center, Sun yat-sen university, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER